Marc Wefers, Ph.D., is a principal in the Boston office of Fish & Richardson P.C. He joined the firm in 1996, having previously served as an associate, patent agent, and technology specialist with the firm. Marc’s practice focuses on patent strategy, including patent prosecution, adversarial proceedings before the U.S. Patent and Trademark Office (USPTO), and litigation, especially in the technical areas of physics, optics, and chemistry. Marc has been lead counsel in five interferences before the USPTO, obtaining a favorable judgment in every instance, two of which have been appealed to, and affirmed by, the U.S. Court of Appeals for the Federal Circuit. Marc is currently lead counsel in a sixth interference, which is ongoing. Marc has also been lead counsel on ten inter-partes review (IPR) proceedings at the USPTO, two for petitioners and eight for patent owners. The two IPR proceedings on behalf of petitioners led to the cancelation of all requested claims, and the eight IPR proceedings for patent owners led to favorable settlements. Prior to such AIA proceedings, Marc was involved in many reexamination proceedings at the USPTO. Marc has also been the technical lead in various patent litigations relating to fiber lasers, fiber amplifiers, and microlithography exposure systems. Marc has also been involved in adversarial patent proceedings in Germany, the Netherlands, and Japan. Representative clients and technologies include: Carl Zeiss SMT GmbH (optical microlithography equipment), Lipocine Inc. (pharmaceutical formulations)., Lightelligence Inc.. (photonics), Fujifilm Electronic Materials USA, Inc. (semiconductor chemistry), IPG Photonics Inc. (fiber lasers and amplifiers), Osram Opto Semiconductors GmbH (light-emitting diodes), WiTricity Inc. (wireless power transfer), Thomas Swan & Co. Ltd. (optical networking equipment), and Zygo Corporation (optical interferometry). Several of Marc’s former start-up clients were acquired on favorable terms: Ahura Scientific Inc. (acquired by Thermo Fisher Scientific in 2010 for $145 million) and Rhythmia Medical Inc. (acquired by Boston Scientific in 2012 for $90 million, and an additional $175 million in contingent payments).
Fish & Richardson P. C.
Firm Prospects attorney tracking launched in 2015/2016. Prior employment history currently unavailable.